Influenza virus vaccine quadrivalent - Medicago

Drug Profile

Influenza virus vaccine quadrivalent - Medicago

Alternative Names: Quadrivalent seasonal influenza VLP vaccine - Medicago; Seasonal influenza vaccine quadrivalent - Medicago; Seasonal influenza virus-like particle (VLP) vaccine - Medicago

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medicago
  • Class Influenza virus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Influenza virus infections

Most Recent Events

  • 29 Sep 2017 Medicago initiates enrolment in a phase III trial for Influenza virus infections (Prevention, In adults) in Canada (NCT03321968)
  • 26 Sep 2017 Medicago plans to launch Influenza virus vaccine quadrivalent in Canada, USA and Europe in 2020
  • 26 Sep 2017 Phase-III clinical trials in Influenza virus infections (Prevention, In adults) in USA, Canada, United Kingdom, Thailand, and the Philippines (IM) (EudraCT2017-001239-38)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top